Skip to content

Study · Case report or series · n = 1 · 2025

2 results

Is Semaglutide Linked to NAION? A Case Report on a Rare Ocular Complication.

Lešin Gaćina D, Vidović T, Vlajić Oreb N, Matković L, Jandroković S

Reports (MDPI)20 Aug 2025Cited by 4 (Europe PMC)

PMID40843891 (opens in a new tab)PMCIDPMC12372079 (opens in a new tab)DOI10.3390/reports8030149 (opens in a new tab)PepBankPUB-40843891
Download PDFPubMedAsk about this study
Jump to 2 results

Summary

Background and Clinical Significance: Ischemic optic neuropathies (IONs) are significant causes of vision loss resulting from compromised blood flow to the optic nerve. Diabetes mellitus (DM) exacerbates the risk of IONs through chronic hyperglycemia and associated vascular dysfunction. Recently, semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has been linked to ocular complications, including non-arteritic anterior ischemic optic neuropathy (NAION), potentially due to the rapid glycemic changes or vascular effects. Case Presentation: A 55-year-old female with type 2 DM, hypertension, and hyperlipidemia presented with blurred vision and optic disc edema after four months of semaglutide therapy (Ozempic®, Sydney, Australia). Initially diagnosed with diabetic papillopathy (DP), her condition progressed to NAION, leading to partial visual recovery with corticosteroid treatment and improved glycemic management. Diagnostic evaluations, including visual field testing, optical coherence tomography, and fluorescein angiography, supported the diagnosis. Conclusions: This case report describes the clinical course of a diabetic patient treated with a semaglutide who developed an ischemic optic event. The timing of symptom onset in relation to the initiation of semaglutide therapy raises the possibility of a causal association between the drug and this rare ocular complication. Close monitoring of ocular health is crucial for patients on GLP-1 receptor agonists, particularly those with pre-existing vascular risk factors. Further research is needed to elucidate the underlying mechanisms and guide clinical practice.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanCase report or seriesSafety outcome

    In a 55-year-old woman with type 2 diabetes, hypertension and hyperlipidemia, blurred vision and optic disc edema appeared after four months of semaglutide.

    In plain wordsOne woman with type 2 diabetes developed blurred vision and swelling of the optic nerve disc after four months on semaglutide.

    Peptide
    Semaglutide
    Outcome
    IncreaseBlurred vision and optic disc edema after four months of semaglutide
    Study

    n = 1

    Outcome group
    Adverse events · Eye
    Studied dose
    Dose not stated · four months before onsetAs given in this study (human).

    Source sentences

    Summary
    A 55-year-old female with type 2 DM, hypertension, and hyperlipidemia presented with blurred vision and optic disc edema after four months of semaglutide therapy (Ozempic®, Sydney, Australia).
  2. 02HumanCase report or seriesSafety outcome

    In the same patient, an initial diagnosis of diabetic papillopathy progressed to NAION while on semaglutide.

    In plain wordsIn this woman, an optic nerve problem first diagnosed as diabetic papillopathy progressed to a blood-flow related optic nerve injury while she took semaglutide.

    Peptide
    Semaglutide
    Outcome
    IncreaseProgression to non-arteritic anterior ischemic optic neuropathy (NAION)
    Study

    n = 1

    Outcome group
    Adverse events · Eye
    Studied dose
    Dose not stated · four months before onsetAs given in this study (human).

    Source sentences

    Summary
    Initially diagnosed with diabetic papillopathy (DP), her condition progressed to NAION
    1 context sentence
    Summary · context
    A 55-year-old female with type 2 DM, hypertension, and hyperlipidemia presented with blurred vision and optic disc edema after four months of semaglutide therapy (Ozempic®, Sydney, Australia).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.